Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He is currently a director of Liquidia Technologies, Cognoa, K-Gen, Artugen Therapeutics, Cognito Therapeutics, Amylyx Pharmaceuticals, and NuCana BioMed. Previously he was a board member of Advanced Cell Diagnostics (sold to Bio-Techne). Prior to j...
Roles at Amylyx